Pregabalin for the management of partial epilepsy

Neuropsychiatric Disease and Treatment

Volumn 4, Issue 6, 2008, Pages 1211-1224

  Ryvlin, Philippe ^a   Perucca, Emilio ^b,c   Rheims, Sylvain ^a  

^a UNIVERSITÉ LYON 1   (France)

^b C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

Adjunctive therapy; Antiepileptic drugs; Clinical trials; Efficacy; Partial seizures; Pregabalin; Tolerability

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; DIURETIC AGENT; ETIRACETAM; GABAPENTIN; INSULIN; LAMOTRIGINE; ORAL ANTIDIABETIC AGENT; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; PARACETAMOL; PHENOBARBITAL; PHENYTOIN; PLACEBO; PREGABALIN; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ACCIDENTAL INJURY; ADJUVANT THERAPY; AMBLYOPIA; AMNESIA; ANTICONVULSANT ACTIVITY; ANXIETY; ARTICLE; ASTHENIA; ATAXIA; ATTENTION DISTURBANCE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONFUSION; CREATININE CLEARANCE; DIPLOPIA; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; FATIGUE; FOCAL EPILEPSY; GYNECOMASTIA; HUMAN; INSOMNIA; MYOCLONUS; NERVOUSNESS; NONHUMAN; PERIPHERAL EDEMA; SEDATION; SIDE EFFECT; SOMNOLENCE; THOUGHT DISORDER; VISUAL DISORDER; WEIGHT GAIN;

EID: 60249088840     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: 10.2147/ndt.s4716     Document Type: Article

References (55)

1. Arroyo S, Anhut H, Kugler AR, et al. 2004. Pregabalin add-on treatment: a randomized double-blind placebo-controlled dose-response study in adults with partial seizures. Epilepsia, 45:20-7.
2. Bandelow B, Wedekind D, Leon T. 2007. Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention. Expert Rev Neurother, 7:769-81.
3. Ben-Menachem E. 2004. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia, 45(Suppl 6):13-8.
4. Beydoun A, Uthman BM, Kugler AR, et al. 2005. Safety and efficacy of two pregabalin regimens for partial epilepsy: an add-on, placebo-controlled trial. Neurology, 64:475-80.
5. Beydoun A, Nasreddine W, Atweh S. 2008. Efficacy and tolerability of pregabalin in partial epilepsy. Expert Rev Neurother, 8:1013-24.
6. Blommel ML, Blommel AL. 2007. Pregabalin: an antiepileptic agent useful for neuropathic pain. Am J Health Syst Pharm, 64:1475-82.
7. Bockbrader HN, Miller R, Frame B, et al. 2005. The concomitant use of pregabalin and oral contraceptives does not affect the efficacy of either agent. Epilepsia, 46(Suppl 8): 170.
8. Briggs DE, Lee CM, Spiegel K, et al. 2008. Reduction of secondarily generalized tonic-clonic (SGTC) seizures with pregabalin. Epilepsy Res.
9. Brodie MJ. 2004. Pregabalin as adjunctive therapy for partial seizures. Epilepsia, 45(Suppl 6): 19-27.
10. Brodie MJ, Wilson EA, Wesche DA, et al. 2005. Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, andvalproate in patients with partial epilepsy. Epilepsia, 46:1407-13.
11. Committee for Proprietary Medicinal Products (CPMP). 2000. Note for guidance on clinical investigation of medicinal products in the treatment of epileptic disorders. CPMP/EWP/566/98revl. London. Accessed on 25 August 2006. URL: www.emea.eu.int/pdfs/human/ewp/056698en.pdf
12. Cramer JA, Fisher R, Ben-Menachem E, et al. 1999. New antiepileptic drugs: comparison of key clinical trials. Epilepsia, 40:590-600.
13. Cundy KC, Sastry S, Luo W, et al. 2008. Clinical pharmacokinetics of XP13512, a novel transported prodrug of Gabapentin. J Clin Pharmacol. (Sept 30, Epub ahead of print).
14. Dooley DJ, Donovan CM, Meder WP, et al. 2002. Preferential action of gabapentin and pregabalin at P/Q-type voltage-sensitive calcium channels: inhibition of K+-evoked [3H]-norepinephrine release from rat neocortical slices. Synapse, 45:171-90.
15. Elger CE, Brodie MJ, Anhut H, et al. 2005. Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexible-dose and fixed-dose treatment in a double-blind, placebo-controlled study. Epilepsia, 46:1926-36.
16. Errante LD, Petroff OA. 2002. Acute effects of gabapentin and pregabalin on rat forebrain cellular GABA, glutamate, and glutamine concentrations. Seizure, 12:300-6.
17. Feng MR, Turluck D, Burleigh J, et al. 2001. Brain microdialysis and PK/ PD correlation of pregabalin in rats. Eur J Drug Metab Pharmacokinet, 26:123-8.
18. Ferrendelli JA. 2001. Concerns with antiepileptic drug initiation: safety, tolerability, and efficacy. Epilepsia, 42(Suppl 4):28-30.
19. Fink K, Dooley DJ, Meder WP, et al. 2002. Inhibition of neuronal Ca2+ influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology, 42:229-36.
20. Frampton JE, Scott LJ. 2004. Pregabalin: in the treatment of painful diabetic peripheral neuropathy. Drugs, 64:2813-20.
21. Freeman R, Durso-Decruz E, Emir B. 2008. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care, 31:1448-54.
22. French J, Arrigo C. 2005. Rapid onset of action of levetiracetam in refractory epilepsy patients. Epilepsia, 46:324-6.
23. French JA, Kugler AR, Robbins JL, et al. 2003. Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology, 60:1631-7.
24. Gazzola DM, Balcer LJ, French JA. 2007. Seizure-free outcome in randomized add-on trials of the new antiepileptic drugs. Epilepsia, 48:1303-7.
25. Hellwig S, Amtage F. 2008. Pregabalin-induced cortical negative myoclonus in a patient with neuropathic pain. Epilepsy Behav, 13:418-20.
26. Hitiris N, Barrett JA, Brodie MJ. 2006.Erectile dysfunction associated with pregabalin add-on treatment in patients with partial seizures: five case reports. Epilepsy Behav, 8:418-21.
27. Hoppe C, Rademacher M, Hoffmann JM, et al. 2008. Bodyweight gain under pregabalin therapy in epilepsy: Mitigation by counseling patients? Seizure, 17:327-32.
28. Huppertz HJ, Feuerstein TJ, Schulze-Bonhage A. 2001. Myoclonus in epilepsy patients with anticonvulsive add-on therapy with pregabalin. Epilepsia, 42:790-2.
29. Janiczek-Dolphin N, Corrigan BW, Bockbrader HN. 2005. Diuretics, oral hypoglycemic agents, and insulin do not alter pregabalin pharmacokinetics. Epilepsia, 46(Suppl 6):115.
30. Jezyk N, Li C, Stewart BH, et al. 1999. Transport of pregabalin in rat intestine and Caco-2 monolayers. Pharm Res, 16:519-26.
31. Kälviäinen R, Khyuppenen J, Koskenkorva P, et al. 2008. Clinical picture of EPM 1-Unverricht-Lundborg disease. Epilepsia, 49:549-56.
32. Leppik I, De Rue K, Edrich P, et al. 2006. Measurement of seizure freedom in adjunctive therapy studies in refractory partial epilepsy: the levetiracetam experience. Epileptic Disord, 8:118-30.
33. Li Z, Donevan S, Taylor, et al. 2005. High-affinity binding of pregabalin at alpha-2-delta subunits of voltage-gated calcium channel: Contribution to anticonvulsant action. Epilepsia, 46(Suppl 6):280.
34. Lozsadi D, Hemming K, Marson AG. 2008. Pregabalin add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 1:CD005612.
35. Málaga I, Saumarti FX. 2006. Two cases of painful gynecomastia and lower extremity pain in association with pregabalin therapy. Epilepsia, 47:1576-9.
36. May T, Rambeck B, Neb R, et al. 2007. Serum concentrations of pregabalin in patients with epilepsy: The influence of dose, age, and comedication. Ther Drug Monit, 29:789-94.
37. McLean MJ. 1994. Clinical pharmacokinetics of gabapentin. Neurology, 44(Suppl 5):S17-22.
38. Modur PN, Milteer WE. 2008. Adjunctive pregabalin therapy in mentally retarded, developmentally delayed patients with epilepsy. Epilepsy Behav, 13:554-6.
39. Mohanraj R, Brodie MJ. 2003. Measuring the efficacy of antiepileptic drugs. Seizure, 12:413-43.
40. Owen RT. 2007. Pregabalin: its efficacy, safety and tolerability profile in generalized anxiety. Drugs Today, 43:601-10.
41. Perucca E. 2002. What can we learn from clinical trials of anticonvulsant drugs in epilepsy? Eur J Pain, 6(Suppl A):35-44.
42. Perucca E. 2006. Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age. Clin Pharmacokinet, 45:351-63.
43. Perucca E. 2008. Designing clinical trials to assess antiepileptic drugs as monotherapy: difficulties and solutions. CNS Drugs, 22:917-38.
44. Perucca E, Robbins JL, Kugler et al. 2002. Pregabalin demonstrates anticonvulsant activity onset by the second day. Epilepsia, 43(Suppl 8):48.
45. Piyapolrungroj N, Li C, Bockbrader H, et al. 2001. Mucosal uptake of gabapentin (neurontin) vs. pregabalin in the small intestine. Pharm Res, 18:1126-30.
46. Randinitis EJ, Posvar EL, Alvey CW, et al. 2003. Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J Clin Pharmacol, 43:277-83.
47. Rheims S, Cucherat M, Arzimanoglou A, et al. 2008. Greater response to placebo in children than in adults: a systematic review and meta-analysis in drug-resistant partial epilepsy. PLoS Med, 5, e166:1223-36.
48. Ryvlin P. 2005. Defining success in clinical trials - profiling pregabalin, the newest AED. Eur J Neurol, (Suppl) 4:12-21.
49. Ryvlin P, Rheims S, Semah F, et al. 2006. Meta-Analysis of add-on treatment in drag resistant partial epilepsy: a comprehensive study of 41 randomized controlled trials among 10 AEDs. Neurology, 66(Suppl 2):A36.
50. Shneker BF, McAuley JW. 2005. Pregabalin: a new neuromodulator with broad therapeutic indications. Ann Pharmacother, 39:2029-37.
51. Tassone DM, Boyce E, Guyer J, et al. 2007. Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin Ther, 29:26-48.
52. Taylor CP, Vartanian MG. 1997. Profile of the anticonvulsant activity of CI-1008 (pregabalin) in animal models. Epilepsia, 38(Suppl 8):8.
53. Vartanian MG, Radulovic LL, Kinsora JJ, et al. 2006. Activity profile of pregabalin French JA (2001). Proof of efficacy trials: endpoints. Epilepsy Res, 45:53-6.
54. Walker MC, Sander JW 1996. The impact of new antiepileptic drugs on the prognosis of epilepsy: seizure freedom should be the ultimate goal. Neurology, 46:912-4.
55. Warner G, Figgit DP. 2005. Pregabalin as adjunctive treatment of partial seizures. CNS Drugs, 19:265-72.